WHO head denounces vaccine inequity as COVAX scheme marks first year | Inquirer News

WHO head denounces vaccine inequity as COVAX scheme marks first year

/ 12:03 AM April 24, 2021

 A nurse prepares to administer the AstraZeneca/Oxford vaccine under the COVAX scheme against the coronavirus disease (COVID-19) at the Eka Kotebe General Hospital in Addis Ababa, Ethiopia March 13, 2021. REUTERS/Tiksa Negeri

A nurse prepares to administer the AstraZeneca/Oxford vaccine under the COVAX scheme against the coronavirus disease (COVID-19) at the Eka Kotebe General Hospital in Addis Ababa, Ethiopia March 13, 2021. REUTERS/Tiksa Negeri

GENEVA  – Coronavirus vaccines remain out of reach in the poorest countries, the head of the World Health Organization (WHO) said in a report on Friday, marking the first anniversary of the COVAX dose-sharing facility.

“Nearly 900 million vaccine doses have been administered globally, but over 81% have gone to high- or upper middle-income countries, while low-income countries have received just 0.3%,” WHO director-general Tedros Adhanom Ghebreyesus said about the ACT (Access to COVID-19 Tools) Accelerator set up a year ago.

Article continues after this advertisement

He later told a briefing he was concerned about the rising caseload in India.

FEATURED STORIES

India reported the world’s highest daily tally of coronavirus infections for a second day on Friday, surpassing 330,000 new cases, as it struggles with a health system overwhelmed by patients and plagued by accidents and lack of medical oxygen.

“The situation in India is a devastating reminder of what the virus can do,” he told a virtual briefing.

Article continues after this advertisement

Tedros has repeatedly denounced inequities in vaccine distribution and urged wealthier countries to share excess doses to help inoculate health workers in low-income countries. More than 3 million people have died in the pandemic.

Article continues after this advertisement

“Continued lack of financial support for the ACT Accelerator poses a major obstacle for its ability to deliver at scale” Dag Ulstein, Norwegian minister of international development, told the same briefing.

Article continues after this advertisement

COVAX, which has shipped 40.5 million doses to 118 countries so far, aims to secure 2 billion doses by the end of 2021.

On Thursday, COVAX, co-run by the Gavi Vaccine Alliance and WHO, said it was seeking to bolster its supplies of vaccines for poor countries from new manufacturers as it aims to mitigate supply problems of the AstraZeneca vaccine from India, its main shot so far.

Article continues after this advertisement

“Low-income countries test less than 5% as much as high-income countries, and the majority of countries still have trouble accessing sufficient oxygen and dexamethasone,” Tedros said. He was referring to an inexpensive steroid found to help patients suffering severe COVID-19, the only WHO-approved treatment for the disease.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Covax, COVID-19, vaccine, WHO

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.